Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group

Abstract

Erlotinib monotherapy showed significant antitumor activity and an acceptable tolerability profile as a palliative treatment in advanced NSCLC patients in Korea, especially in females, never smokers, and patients with adenocarcinoma histology.

Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan

“…We found that there were no associations between achievement of disease control or response to erlotinib and independent factors including smoking history, adenocarcinoma in tumor histology, presence of EGFR mutation in cancer cells and skin adverse effects. These are not consistent with the results previously described [3,6,14]. The reasons are unclear.…”

“…We demonstrated here that erlotinib showed high DCR, as previously described [6,14]. Furthermore, its AEs were tolerable and seemed to be equivalent to those in the Asian population as reported previously, but the incidence of IP in this study is much higher than that observed in Caucasians, as shown in the BR.21 study [3].…”

Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

“…Therefore, we performed subgroupanalysis according to geographic origin and found that EGFR-TKIs monotherapy significantly improved PFS and ORR in East Asian patients, but it did not translate into increase in OS and 1-year SR. In addition, we also found that the characters that well known to affect the efficacy and survival to EGFR-TKIs therapy, such as high proportions of female patients, never-smokers, and patients with adenocarcinoma histology (Shepherd et al, 2005;Thatcher et al, 2005;Uhm et al, 2009), were not substantially different between unselected patients receiving EGFR-TKIs and receiving single-agent therapy in this study except for the most recent trial conducted by Sun et al (2012). The KCSG-LU08-01 study aimed to compare the efficacy of gefitinib with pemetrexed as second-line treatment in patients with advanced NSCLC.…”

Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment

“…This finding was similar to that of a recent Asian study. Uhm et al [16] reported that, on a multivariate level, smoking status did not retain statistical significance for OS (p = 0.833) and time to progression (p = 0.218) in advanced NSCL patients treated with erlotinib as a salvage therapy. These discrepancies were thought to be due to the dissimilarity of the baseline characteristics, especially ethnicity, of patients across studies [9,10,14].…”